Zevra TherapeuticsZVRA
About: Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Employees: 69
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
228% more call options, than puts
Call options by funds: $985K | Put options by funds: $300K
200% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 14
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
11% more capital invested
Capital invested by funds: $81.2M [Q1] → $90.4M (+$9.21M) [Q2]
9.61% more ownership
Funds ownership: 34.51% [Q1] → 44.12% (+9.61%) [Q2]
4% more funds holding
Funds holding: 89 [Q1] → 93 (+4) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Guggenheim | 139%upside $20 | Buy Initiated | 7 Oct 2024 |
HC Wainwright & Co. Oren Livnat 40% 1-year accuracy 14 / 35 met price target | 139%upside $20 | Buy Reiterated | 30 Sept 2024 |
JMP Securities Jason Butler 45% 1-year accuracy 19 / 42 met price target | 103%upside $17 | Market Outperform Initiated | 24 Sept 2024 |
Maxim Group Jason McCarthy 22% 1-year accuracy 4 / 18 met price target | 198%upside $25 | Buy Maintained | 24 Sept 2024 |
Roth MKM Jonathan Aschoff 10% 1-year accuracy 2 / 20 met price target | 151%upside $21 | Buy Maintained | 24 Sept 2024 |
Financial journalist opinion
Based on 6 articles about ZVRA published over the past 30 days